MYOMO, INC.
MYONYSE
$0.95
↓ -9.5%Jul 17 close · end-of-day
Price
1Y↓ -51.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$40.2M
Enterprise Value
$35.4M
P/E
—
P/S
1.0
P/B
4.5
EV/EBITDA
—
PEG
—
FCF Yield
-38.4%
Dividend Yield
—
Revenue (TTM)
$41.2M
Net Income (TTM)
-$15.1M
Free Cash Flow (TTM)
-$15.4M
Gross Margin
66.0%
Operating Margin
-34.1%
Net Margin
-36.8%
ROE
-168.2%
ROIC
-262.1%
Debt / Equity
1.2
Net Cash
$4.8M
Return 1Y
-53.6%
Company profile
MyoPro is a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals.
- CEO
- Paul R. Gudonis
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 90
- Headquarters
- Massachusetts
- Website
- myomo.com
Management & directors
- Henry David AChief Financial Officer
- Gudonis Paul RChief Executive Officer
- Kovelman HarryChief Medical Officer
- Mitchell MicahChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
MYO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.1M↑ +2.9%
Diluted EPS-$0.07↓ -12.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.6M | $13.9M | $15.6M | $19.2M | $32.6M | $40.9M |
| Gross profit | $5.0M | $10.3M | $10.3M | $13.2M | $23.2M | $26.9M |
| Operating income | -$10.5M | -$10.3M | -$10.7M | -$8.2M | -$6.2M | -$14.4M |
| Net income | -$11.6M | -$10.4M | -$10.7M | -$8.1M | -$6.2M | -$15.6M |
| Diluted EPS | — | -$1.89 | -$1.52 | -$0.28 | -$0.16 | -$0.37 |
| Operating cash flow | -$9.0M | -$9.5M | -$10.2M | -$6.2M | -$3.3M | -$14.5M |
| Free cash flow | -$9.1M | -$9.9M | -$10.3M | -$6.3M | -$4.7M | -$16.3M |
| Gross margin | 65.7% | 74.4% | 65.9% | 68.5% | 71.2% | 65.7% |
| Operating margin | -138.5% | -74.1% | -68.6% | -42.8% | -19.1% | -35.2% |
| Net margin | -152.5% | -74.9% | -68.9% | -42.1% | -19.0% | -38.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.2M | $12.1M | $9.8M | $9.7M | $10.1M | $11.4M | $10.1M |
| Gross profit | $5.3M | $6.9M | $8.6M | $6.6M | $6.1M | $6.4M | $7.8M | $6.9M |
| Operating income | -$1.1M | -$957,553.00 | -$245,314.00 | -$3.5M | -$4.6M | -$3.5M | -$2.8M | -$3.2M |
| Net income | -$1.1M | -$966,409.00 | -$276,352.00 | -$3.5M | -$4.6M | -$3.7M | -$3.8M | -$3.0M |
| Diluted EPS | -$0.03 | -$0.03 | $0.00 | -$0.08 | -$0.11 | -$0.09 | -$0.09 | -$0.07 |
| Operating cash flow | -$1.9M | -$1.5M | $3.4M | -$2.7M | -$8.9M | -$1.8M | -$1.1M | -$2.2M |
| Free cash flow | -$2.0M | -$1.8M | $2.5M | -$3.3M | -$10.1M | -$2.9M | -$2.4M | -$2.5M |
| Gross margin | 70.8% | 75.4% | 71.4% | 67.2% | 62.7% | 63.8% | 68.6% | 68.2% |
| Operating margin | -14.8% | -10.4% | -2.0% | -35.8% | -47.6% | -34.9% | -24.4% | -31.2% |
| Net margin | -14.9% | -10.5% | -2.3% | -35.2% | -48.0% | -36.3% | -33.8% | -29.8% |
Company news
Jun 23, 2026
Jun 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | HENRY DAVID A· Chief Financial Officer | Tax withholding | 5,166 | $1.09 | $5,630.94 | filing |
| 2026-07-10 | HENRY DAVID A· Chief Financial Officer | Award | 7,840 | $0.00 | $0.00 | filing |
| 2026-07-10 | GUDONIS PAUL R· Chief Executive Officer | Award | 10,454 | $0.00 | $0.00 | filing |
| 2026-06-25 | Manko Joseph M. Jr. | Award | 78,704 | $0.00 | $0.00 | filing |
| 2026-06-25 | Crowley Thomas Aloysius Jr. | Award | 78,704 | $0.00 | $0.00 | filing |
| 2026-06-25 | KIRK THOMAS F | Award | 78,704 | $0.00 | $0.00 | filing |
| 2026-06-25 | Getz Heather C | Award | 78,704 | $0.00 | $0.00 | filing |
| 2026-06-25 | FEBBO WILLIAM J | Award | 78,704 | $0.00 | $0.00 | filing |
| 2026-06-25 | Morris Milton Mayo | Award | 78,704 | $0.00 | $0.00 | filing |
| 2026-06-12 | Kovelman Harry· Chief Medical Officer | Tax withholding | 10,442 | $1.20 | $12,530.40 | filing |
| 2026-06-12 | Mitchell Micah· Chief Commercial Officer | Tax withholding | 9,061 | $1.20 | $10,873.20 | filing |
| 2026-06-12 | HENRY DAVID A· Chief Financial Officer | Tax withholding | 10,969 | $0.00 | $0.00 | filing |
| 2026-06-08 | Kovelman Harry· Chief Medical Officer | Tax withholding | 7,635 | $1.33 | $10,154.55 | filing |
| 2026-06-08 | Mitchell Micah· Chief Commercial Officer | Tax withholding | 6,529 | $1.33 | $8,683.57 | filing |
| 2026-06-08 | HENRY DAVID A· Chief Financial Officer | Tax withholding | 10,050 | $0.00 | $0.00 | filing |
| 2026-06-05 | KIRK THOMAS F | Buy | 40,002 | $1.27 | $50,802.54 | filing |
| 2026-05-28 | KIRK THOMAS F | Buy | 25,000 | $0.99 | $24,825.00 | filing |
| 2026-05-28 | Kovelman Harry· Chief Medical Officer | Sale | 11,536 | $1.02 | $11,734.42 | filing |
| 2026-05-27 | Kovelman Harry· Chief Medical Officer | Sale | 20,464 | $1.00 | $20,504.93 | filing |
| 2026-05-18 | KIRK THOMAS F | Buy | 43,401 | $0.91 | $39,494.91 | filing |
| 2026-05-15 | KIRK THOMAS F | Buy | 31,605 | $0.91 | $28,747.91 | filing |
| 2026-05-15 | Manko Joseph M. Jr. | Buy | 30,367 | $0.89 | $26,959.82 | filing |
| 2026-05-14 | Manko Joseph M. Jr. | Buy | 170,830 | $0.86 | $146,947.97 | filing |
| 2026-05-14 | Mitchell Micah· Chief Commercial Officer | Sale | 90,231 | $0.86 | $77,688.89 | filing |
| 2026-04-14 | FEBBO WILLIAM J | Award | 45,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.